在帕金森病的语音障碍中,对右小脑进行连续的达爆发刺激:随机化,假控,临床试验的研究方案
Xiaoxia Zhu1, Guangyan Dai1, Meng Wang2
1Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Frontiers in aging neuroscience
|September 1, 2023
概括
这项研究调查了大脑小脑连续爆刺激 (cTBS) 与语音治疗相结合是否能改善帕金森病 (PD) 的语言. 这些发现将为PD相关的沟通困难的新疗法提供指导.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 语音语言病理学 语言病理学
背景情况:
- 发言障碍是帕金森病 (PD) 的一个重大挑战,影响生活质量.
- 目前对PD的治疗方法对言语障碍提供了有限的益处.
- 小脑功能障碍与PD相关的语言障碍有关.
研究的目的:
- 为了评估结合小脑连续甲突破刺激 (cTBS) 与语音语言治疗 (SLT) 治疗PD语音障碍的疗效.
- 探索大脑小脑cTBS对PD语音产生的影响背后的神经机制.
主要方法:
- 一项随机对照试验 (RCT) 涉及40名PD患者.
- 实验组接受了真正的cTBS在右小脑上加SLT;对照组接受了假刺激加SLT.
- 结果评估了干预前,干预后和12周的随访,包括语音质量,听觉-语音整合,认知,生活质量和基于fMRI的功能连接.
主要成果:
- 结果正在等待,因为这是一个试验设计.
- 该研究旨在测量语音/言语质量和听觉-语音整合方面的改进.
- 二次结果包括认知功能,生活质量和大脑连接的变化.
结论:
- 这项试验旨在提供关于小脑cTBS作为PD语音障碍新治疗方法的有效性和安全性的证据.
- 这些发现可能有助于了解小脑功能障碍及其在语言障碍中的作用.
- 这项研究可以为其他涉及小脑相关语音缺陷的疾病提供干预信息.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593


